Intrepid Financial Planning Group LLC Has $1.92 Million Stake in Novo Nordisk A/S (NYSE:NVO)

Intrepid Financial Planning Group LLC lowered its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 3.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,448 shares of the company’s stock after selling 460 shares during the period. Intrepid Financial Planning Group LLC’s holdings in Novo Nordisk A/S were worth $1,920,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. 1620 Investment Advisors Inc. bought a new stake in Novo Nordisk A/S in the second quarter valued at about $25,000. Gilliland Jeter Wealth Management LLC boosted its holdings in Novo Nordisk A/S by 200.0% during the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after purchasing an additional 120 shares in the last quarter. First PREMIER Bank bought a new stake in shares of Novo Nordisk A/S in the 1st quarter valued at approximately $25,000. Dixon Mitchell Investment Counsel Inc. acquired a new position in shares of Novo Nordisk A/S in the 1st quarter worth approximately $26,000. Finally, Orion Capital Management LLC bought a new position in shares of Novo Nordisk A/S during the 1st quarter worth approximately $26,000. Institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Monday. BMO Capital Markets reduced their price objective on Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating on the stock in a research note on Thursday, August 8th. The Goldman Sachs Group started coverage on shares of Novo Nordisk A/S in a research note on Thursday, May 30th. They set a “buy” rating and a $156.00 price target on the stock. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Wednesday. Finally, Argus increased their target price on Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research note on Monday, June 10th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Buy” and a consensus target price of $145.17.

Novo Nordisk A/S Price Performance

NVO opened at $132.09 on Thursday. The stock has a market cap of $592.76 billion, a P/E ratio of 45.55, a P/E/G ratio of 1.48 and a beta of 0.42. Novo Nordisk A/S has a 12 month low of $86.96 and a 12 month high of $148.15. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.46. The company has a fifty day simple moving average of $133.52 and a 200 day simple moving average of $133.19.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $0.65 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.71 by ($0.06). The business had revenue of $9.82 billion during the quarter, compared to analyst estimates of $9.91 billion. Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. On average, research analysts expect that Novo Nordisk A/S will post 3.11 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 16th were issued a dividend of $0.5126 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a dividend yield of 0.7%. Novo Nordisk A/S’s payout ratio is 24.83%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.